Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (March 2017)
21 slides from Inspiremd's investor presentation, Mar 29, 2017
Slide 1: Investor Presentation
inspireMD Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspirelD This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forw
Slide 3: About InspireMD
About InspireMD inspirel InspireMD is a commercial-stage medical device company with proprietary and innovative embolic prevention systems (EPS)/thrombus management technologies and neurovascular devices that seek to overcome the harmful consequences of conventional stenting. TECHNOLOGY Proprietary
Slide 4: Investment Highlights
Investment Highlights inspireMD ¢ Multi-billion dollar opportunity for MicroNet™ products for multiple vascular markets * Current stents do not adequately address the risk of post-procedural embolization * Consistent positive clinical trial results positioning CGuard™ as a potential standard-of-care
Slide 5: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD “Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization,
Slide 6: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit to Stroke Pre-Procedure Post-Procedure Pre-intervention showing 90% occlusion of the Post-intervention showing successful opening carotid artery and an MRI showing an old white of the occluded carotid artery with conventional matter infarction (obstructio
Slide 7: MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges
MicroNet™ Prevents Distal Embolization and Other Vascular Disease Challenges inspire ¢ Ultrathin PET* mesh provides meaningful clinical benefit versus conventional devices ¢ Provides revascularization benefit * MicroNet™ acts as a “safety net” by offering greater vessel area coverage to prevent larg
Slide 8: Large & Growing Addressable Market
Large & Growing Addressable Market inspireMD Embolic Prevention Products CGuard™ $500M Y Carotid MGuard™* $1.7B Y Coronary AMI & SVG Planned NGuard™ $675M Submission Neurovascular TBD Planned PVGuard™ $1.7B Submission Peripheral TBD *MGuard™ global strategy focused on drug eluting stent OEM partners
Slide 9: CGuard Product Development
CGuard™ Product Development inspireMD « US FDA ¢ Pre-IDE FDA submission for CGuard™ completed * Formal FDA meeting planned 1) / \ ¢ Planned IDE submission in 2018 ¢ Next generation CGuard™ - 5 French CGuard™ * Minimally invasive devices trending smaller for broader and easier usage * Lower profile s
Slide 10: Positive CGuard Clinical Experience
Positive CGuard™ Clinical Experience inspireMD CARENET Clinical Trial (2014) PARADIGM 101 Clinical Trial (2015 and 2016) 30 Patient Safety and Efficacy clinical trial Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") 50% fewer new ischemic lesions with lesion
Slide 11: Additional Independent Clinical Data Supports Use of CGuard
Additional Independent Clinical Data Supports inspii reMD Use of CGuard™ Independent study conducted in 30 patients with internal carotid artery disease Clinical results (2016) * 100% success in implanting the CGuard™ EPS * No peri- or post-procedural complications ¢ No deaths, major adverse events,
Slide 12: Additional Independent Clinical Data Presented at LINC 2017
Additional Independent Clinical Data Presented “Ne at LINC 2017 Further Supports Use of CGuard™ ‘nspireMD SPECIAL ARTICLES The Iron-Guard Registry cana ae aSreet « Physician initiated oe ; ; ; a + Physician-initiated prospective Italian Registry * 12 large Italian medical centers of carotid stenting
Slide 13: Sales & Marketing Strategy
Sales & Marketing Strategy inspireMD Proven success with regionally strong local distributors; YOY sales growth 67% Representative Regional Distributors Colombia 100% Israel 151% Italy 59% Slovenia 95% Chile 233% « Replacing Penumbra with regional distributors who target all 4 clinical specialties;
Slide 14: Europe
USS Europe PD Dr. Andrej Schmidt and Dr. Sven Braunlich from the Department of Angiology, University Hospital Leipzig, Division of Interventional Angiology, Leipzig, Germany, perform a live stent endovascular interventional procedure featuring the CGuard™ EPS Carotid Stent at the Leipzig Interventio
Slide 15: Broad Platform Technology
Broad Platform Technology RGuard™ Renal* NGuard™ Neurovascular* * Planning & Development Phase MGuard™ Coronary EPS CGuard™ Carotid EPS MicroNet™ Platform Technology PVGuard™ Peripheral* MGuard™ Drug Eluting* inspirelMID 15
Slide 16: Near Term Growth Strategy
Near Term Growth Strategy CGuard™ * Engaging distribution partners in countries with current/near-term regulatory approval * Attracting leading KOLs from around the world * Seeking additional regulatory approvals in countries that accept CE Mark « Recent approval in Russia with plan to launch in fir
Slide 17: Upcoming Anticipated Milestones
Upcoming Anticipated Milestones inspireMD CGuard launch in Russia: H1 2017 EU market expansion: Germany, Italy, Spain, etc. : Begin : CGuard: 2018 distribution in U.S. IDE Asia/Pacific H2 2017 submission CGuard 5 French approval and CGuard launch in India submission and Mexico: H2 2018 2017 Continue
Slide 18: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD ¢ Proprietary platform technology supported by a robust intellectual property portfolio * Continue to strengthen and broaden patent protection globally to enable future pipeline products PATENT RIGHTS ISSUED ALLOWED PENDING Rest of World 17 1 19 18
Slide 19: Leadership
Leadership Significant track records of success President and CEO Dr. James Barry inspireMD Boston, (Pfizer) Scientific @m ®@ Craig Shore CFO Agustin Gago cco Delcath 6. ® angiodynamics CELEM E Dr. Sol Barer Chairman Isaac Blech Vice Chairman on NS Contral . @& a is sapience “scerecor S medgenics th
Slide 20: Financial Snapshot
Financial Snapshot inspirelMID NYSE MKT: NSPR Stock Price (3/24/17): $0.92 Average 3 Month Volume (3/24/17): 299 K Shares Outstanding (3/24/17): 5.6M Shares Outstanding Including full conversion 17.0M of preferred shares (3/24/17): , Market Capitalization including full conversion $15.6 M of preferr
Slide 21: InspireMD
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 [email protected] [email protected]